Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Innovive Pharmaceuticals |
---|---|
Information provided by: | Innovive Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00255333 |
The safety, tolerability and pharmacokinetics of INNO-105, an investigational anticancer drug, are being studied in patients with solid tumors.
Condition | Intervention | Phase |
---|---|---|
Tumors |
Drug: INNO-105 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Maryland | |
University of Maryland Greenebaum Cancer Center | |
Baltimore, Maryland, United States, 21201 | |
United States, Texas | |
Mary Crowley Medical Research Center | |
Dallas, Texas, United States, 75201 |
Principal Investigator: | Casey Cunningham, MD | Mary Crowley Medical Research Center |
Principal Investigator: | Edward Sausville, M.D., Ph.D. | University of Maryland Greenebaum Cancer Center |
Study ID Numbers: | INNO-105-901 |
Study First Received: | November 16, 2005 |
Last Updated: | May 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00255333 History of Changes |
Health Authority: | United States: Food and Drug Administration |